Lactams, Macrocyclic
"Lactams, Macrocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.
Descriptor ID |
D047029
|
MeSH Number(s) |
D02.065.589.327 D04.345.295
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactams, Macrocyclic".
Below are MeSH descriptors whose meaning is more specific than "Lactams, Macrocyclic".
This graph shows the total number of publications written about "Lactams, Macrocyclic" by people in this website by year, and whether "Lactams, Macrocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 | 2002 | 0 | 2 | 2 | 2003 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2008 | 1 | 1 | 2 | 2011 | 2 | 1 | 3 | 2014 | 0 | 2 | 2 | 2017 | 0 | 1 | 1 | 2020 | 1 | 0 | 1 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lactams, Macrocyclic" by people in Profiles.
-
Strohbehn GW, Ratain MJ. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
-
Gorska-Ponikowska M, Kuban-Jankowska A, Marino Gammazza A, Daca A, Wierzbicka JM, Zmijewski MA, Luu HH, Wozniak M, Cappello F. The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model. Int J Mol Sci. 2020 Jan 17; 21(2).
-
Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
-
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
-
Vashist S, Urena L, Gonzalez-Hernandez MB, Choi J, de Rougemont A, Rocha-Pereira J, Neyts J, Hwang S, Wobus CE, Goodfellow I. Molecular chaperone Hsp90 is a therapeutic target for noroviruses. J Virol. 2015 Jun; 89(12):6352-63.
-
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
-
Dickinson BC, Packer MS, Badran AH, Liu DR. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014 Oct 30; 5:5352.
-
De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011 Sep 13; 20(3):400-13.
-
Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30.
-
Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|